IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021

Ogurtsova, Katherine; Guariguata, Leonor; Barengo, Noël C.; Ruiz, Paz Lopez‐Doriga; Sacre, Julian W.; Karuranga, Suvi; Sun, Hong; Boyko, Edward J.; Magliano, Dianna J.

doi:10.1016/j.diabres.2021.109118

Cited by 439 publications

(318 citation statements)

References 29 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…When observing the diabetic situation across the world, the prevalence has been progressively increasing [2]. IDF has stated that about half adults (20-79 years) with diabetes do not know their diabetic situation [3]. DM has been a chronic and multifaced disease leading to significant physical detriment to many patients.…”

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy of Imeglimin (Twymeeg) for Elderly Patient with Type 2 Diabetes Mellitus (T2DM)

OKADA¹,

Bando

Iwatsuki³

et al. 2022

Asp Biomed Clin Case Rep

View full text Add to dashboard Cite

Background: As an oral hypoglycaemic agent (OHA), imeglimin (Twymeeg) has been recently introduced to clinical practice for patients with type 2 diabetes mellitus (T2DM) as Twymeeg. It has beneficial pharmacological mechanisms, which are improving insulin secretion, increasing insulin sensitivity, and decreasing insulin resistance. Case Presentation: The case is 84-year-old man with mild cognitive impairment (MCI) for 3 years. He visited late August, 2021 our clinic for general malaise and was pointed out to have post-prandial blood glucose 336 mg/dL and HbA1c 8.6%. He was diagnosed with T2DM. Results: He was started to be given imeglimin 1000mg twice a day, and then HbA1c value was decreased to 7.3% in 4 weeks and 5.7% in 8 weeks. During 9-12 weeks, he felt loss of appetite and reduced food intake. Biochemical examination on 12 weeks showed decreased values of TP, Alb, HbA1c, glucose, free T3, and normal values of TSH, free T4. Doses of imeglimin were 500 mg twice a day for 9-12 weeks and discontinued after 12 weeks. Discussion: Regarding appetite loss, possible causes may include MCI, previous history of gallbladder dyskinesia, adverse effect of imeglimin, and so on. Further development of research will be expected for imeglimin in the future.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy of Imeglimin (Twymeeg) for Elderly Patient with Type 2 Diabetes Mellitus (T2DM)

OKADA¹,

Bando

Iwatsuki³

et al. 2022

Asp Biomed Clin Case Rep

View full text Add to dashboard Cite

show abstract

“…An estimated 537 million people currently have diabetes worldwide, which makes it the largest global epidemic of the 21st century. 1 Diabetes mellitus is a chronic condition that requires lifelong management through lifestyle interventions, medication use, and diabetes self-management education and support. 2 Diabetic peripheral neuropathy (DPN) is a potential complication of diabetes mellitus.…”

Section: Introductionmentioning

confidence: 99%

Diabetes: how to manage diabetic peripheral neuropathy

Gandhi¹,

Fargo²,

Prasad-Reddy³

et al. 2022

DIC

View full text Add to dashboard Cite

Diabetic peripheral neuropathy (DPN) is a major complication of diabetes mellitus. Tight glycaemic management focused on lowering haemoglobin A1C and increasing time in the target glucose range along with metabolic risk factor management form the cornerstone of DPN prevention. However, there is limited evidence supporting the efficacy of glycaemic and metabolic control in reducing the symptoms and complications of DPN, including pain once painful DPN develops. DPN treatments include pharmacological agents and non-pharmacological interventions such as foot care and lifestyle modifications. Pharmacological agents primarily address pain symptoms, which affect 25–35% of people with DPN. First-line agents include the anticonvulsants pregabalin and gabapentin, the serotonin-norepinephrine reuptake inhibitors duloxetine and venlafaxine, and secondary amine tricyclic antidepressants, including nortriptyline and desipramine. All agents have unique pharmacological, safety and clinical profiles, and agent selection should be guided by the presence of comorbidities, potential for adverse effects, drug interactions and costs. Even with the current treatment options, people are commonly prescribed less than the recommended dose of medications, leading to poor management of DPN symptoms and treatment discontinuation. By keeping up with the latest therapy algorithms and treatment options, healthcare professionals can improve the care for people with DPN.

show abstract

“…1 Without adequate action, International Diabetes Federation projects that 643 million people would develop diabetes by 2030. 2 Obesity, physical inactivity and consumption of energy-dense diets are believed to have contributed to an unprecedented rise in the prevalence of type 2 diabetes worldwide. 3 Furthermore, numerous studies have shown that diabetes is associated not only with mortality but also with a variety of chronic complications, including ischemic heart disease, stroke, peripheral neuropathy, chronic kidney disease and heart failure.…”

Section: Introductionmentioning

confidence: 99%

The relationship between occupational dust exposure and incidence of diabetes in male workers: A retrospective cohort study

et al. 2022

View full text Add to dashboard Cite

Aim: Previous studies have focused on the association between ambient particulate matter and diabetes. However, the relationship between subacute exposure to occupational dust and diabetes has not been explored. We aimed to assess this relationship. Methods: Men who worked in dust-related process factories between January 2013 and December 2017 were recruited from a Korea Health Worker Examination Common Data Model cohort. A history of physician-diagnosed diabetes, use of an anti-diabetic drug, or a fasting blood glucose level of ≥7 mmol/L were considered the criteria to diagnose diabetes. Multivariable time-dependent Cox analysis estimated hazard ratios (HRs) and 95% CIs for incident diabetes associated with exposure to occupational dust exposure; interactions with lifestyle factors were analysed. Sensitivity analyses used propensity score matching and landmark analysis.Results: Among 5141 male participants (median follow-up duration, 3.85 years), 349 participants had diabetes. Occupational dust exposure was related to an increased risk of diabetes in the time-dependent Cox analysis (entire cohort: HR 1.66 [95% CI 1.25-2.19], matched cohort: HR 1. ). The findings showed the same direction in the landmark analysis (HR 1.42 [95% CI 1.01-1.99]).Conclusions: A significant relationship exists between occupational dust exposure and increased risk of diabetes in male workers. Further studies should be conducted to confirm that occupational dust exposure is a possible risk factor for diabetes.

show abstract

IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021

Cited by 439 publications

References 29 publications

Clinical Efficacy of Imeglimin (Twymeeg) for Elderly Patient with Type 2 Diabetes Mellitus (T2DM)

Clinical Efficacy of Imeglimin (Twymeeg) for Elderly Patient with Type 2 Diabetes Mellitus (T2DM)

Diabetes: how to manage diabetic peripheral neuropathy

The relationship between occupational dust exposure and incidence of diabetes in male workers: A retrospective cohort study

Contact Info

Product

Resources

About